Cite
HARVARD Citation
Garcia-Manero, G. et al. (n.d.). 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leukemia research. pp. S57-S58. [Online].